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Antihypertensive	monotherapy	 is	 often	 insufficient	 to	 control	 blood	 pressure	 (BP).	
Several	recent	guidelines	advocate	for	 initial	combination	drug	therapy	in	many	pa-
tients.	This	meta-	analysis	of	seven	randomized,	double-	blind	studies	(N	=	5888)	evalu-
ated	 8	weeks	 of	 olmesartan	 medoxomil	 (OM)–based	 single-	pill	 dual-	combination	
therapy	(OM+amlodipine/azelnidipine	or	hydrochlorothiazide)	vs	OM	monotherapy	in	
adults	with	hypertension.	BP-	lowering	efficacy,	goal	achievement,	and	adverse	events	
were	assessed	in	the	full	cohort	and	subgroups	(elderly/nonelderly	and	patients	with	
and	without	chronic	kidney	disease).	In	the	full	cohort	at	week	8,	for	dual	therapy	vs	
monotherapy,	seated	BP	was	lower	(137.5/86.1	mm	Hg	vs	144.4/89.9	mm	Hg),	and	
the	mean	 change	 from	baseline	 in	BP	 and	BP	 goal	 achievement	 (<140/90	mm	Hg)	
were	greater	 (−22.7/−15.0	mm	Hg	vs	−16.0/−11.3	mm	Hg	and	51.2%	vs	34.7%,	re-
spectively).	Adverse	events	were	similar	between	groups.	BP-	lowering	efficacy	among	
subgroups	mirrored	the	findings	in	the	full	cohort	whereby	changes	were	significantly	
greater	following	OM	dual-	combination	therapy	vs	OM	monotherapy.
1  | INTRODUCTION
Hypertension	is	a	well-	known	risk	factor	for	cardiovascular	disease	and	
contributes	to	the	incidence	of	heart	disease,	stroke,	and	kidney	failure.	
Approximately	one	quarter	of	the	adult	population	in	most	developed	
and	developing	communities	has	hypertension.1	Guidelines	for	blood	
pressure	(BP)	goals	are	under	debate	in	the	face	of	organizational	rec-
ommendations	and	recent	clinical	 trial	data.	Recommendations	from	
the	 Eighth	Joint	National	Committee	 (JNC	8),2	American	 Society	 of	
Hypertension	 (ASH)/International	 Society	 of	 Hypertension	 (ISH),3 
and	 the	 European	 Society	 of	Hypertension	 (ESH)/European	 Society	
of	Cardiology	(ESC)	hypertension	guidelines4	are	broadly	similar.	They	
recommend	a	target	BP	goal	of	<140/90	mm	Hg	for	patients	younger	
than	60	years	or	for	those	with	comorbidities	(chronic	kidney	disease	
[CKD],	 diabetes	mellitus,	 or	 history	of	 cardiovascular	 disease)	 and	 a	
target	BP	goal	of	<150/90	mm	Hg	for	older	patients	(aged	≥60	years).
The	options	for	treatment	are	generally	well	established.	General	
recommendations	 from	 JNC	 8,	 ASH/ISH,	 and	 ESH/ESC	 for	 initial	
pharmacologic	therapy	choices	after	the	failure	of	 lifestyle	 interven-
tions	 include	 angiotensin-	converting	 enzyme	 inhibitors,	 angiotensin	
II	 receptor	blockers	 (ARBs),	 calcium	channel	 blockers,	β-	blockers,	 or	
thiazide-	type	diuretics.2–4
Monotherapy	with	an	antihypertensive	agent	will	only	help	about	
17%	to	23%	of	patients	achieve	their	BP	goal,	and	most	patients	will	
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require	more	than	two	drugs	to	achieve	BP	control.5	Therefore,	major	
hypertension	treatment	guidelines	currently	suggest	that	combination	
antihypertensive	therapy	be	used	initially,	particularly	for	high-	risk	pa-
tients	or	those	with	very	high	baseline	BP.2,4	For	the	general	popula-
tion	(all	ages,	including	patients	with	diabetes	mellitus	but	not	CKD),	
JNC	8	specifically	recommends	that	combination	therapy	be	initiated	
with	 two	 drugs	 simultaneously	 (either	 as	 two	 separate	 pills	 or	 as	 a	
single-	pill	combination)	if	systolic	BP	is	>160	mm	Hg	and/or	diastolic	
BP	is	>100	mm	Hg,	or	if	systolic	BP	is	>20	mm	Hg	above	goal	and/or	
diastolic	BP	 is	>10	mm	Hg	above	goal.2	Ongoing	clinical	trials,	along	
with	updated	societal	guidelines	and	meta-	analyses	of	previously	pub-
lished	studies,	will	continue	to	shape	hypertension	treatment	recom-
mendations	in	the	future.
A	large	body	of	clinical	trial	data	has	demonstrated	that	the	ARB	
olmesartan	medoxomil	(OM)	is	well	tolerated	and	effective	in	reducing	
BP.	OM	has	 been	 shown	 to	 provide	 24-	hour	BP-	lowering	 coverage	
and	has	a	safety	profile	similar	to	that	of	placebo	when	used	as	mono-
therapy	or	in	combination	therapy,6	including	when	used	across	a	wide	
range	of	patient	subgroups	(obese,	elderly,	children,	black,	Hispanic,	or	
those	with	diabetes	mellitus).7-16	In	light	of	the	various	recommenda-
tions	 from	treatment	guidelines	and	clinical	 trials,	 the	current	meta-	
analysis	sought	to	compare	the	efficacy	and	safety	of	OM	single-	pill	
dual-	combination	 therapy	 with	 that	 of	 OM	 monotherapy.	 Analyses	
were	performed	in	the	following	subgroups	of	patients	with	hyperten-
sion:	elderly,	nonelderly,	CKD,	and	non-	CKD.
2  | MATERIALS AND METHODS
2.1 | Database definition and inclusion criteria
An	 integrated	 database	 of	 previously	 locked	 individual	 OM	 clinical	
trial	databases	was	developed	by	Daiichi	Sankyo,	Inc.	(Edison,	NJ)	for	
the	 purpose	 of	 completing	 a	 patient-	level	meta-	analysis.	 The	meta-	
analysis	 included	 completed	 studies	 sponsored	by	 group	 companies	
of	Daiichi	 Sankyo	 globally	 reporting	 the	 efficacy	 and	 safety	of	OM.	
Studies	were	included	if	they	met	the	following	criteria:	randomized,	
double-	blind,	placebo-	or	active-	controlled,	phase	2	through	4	clinical	
trials	and	a	scheduled	double-	blind	treatment	duration	of	≥28	days	for	
the	entire	period	of	parallel	design	or	 for	 the	 first	crossover	period.	
To	be	included	in	the	meta-	analysis,	the	studies	had	to	have	a	double-	
blind	 period	 of	 at	 least	 8	weeks	 including	 patients	 (aged	 ≥18	years)	
with	hypertension	in	which	randomized	treatment	consisted	of	either	
OM	single-	pill	dual-	combination	therapy	with	amlodipine,	azelnidipine,	
or	 hydrochlorothiazide	 compared	with	OM	monotherapy,	 and	 have	
evaluated	BP-	lowering	efficacy	and	BP	goal	achievement	end	points	
(Figure	S1).	Institutional	review	boards	reviewed	and	approved	study	
protocols	per	local	regulations,	and	patients	provided	written	informed	
consent	for	each	individual	study	included	in	the	meta-	analysis.
2.2 | Assessments
Efficacy	end	points	that	were	studied	included	mean	seated	BP	(SeBP;	
included	 seated	 systolic	 BP	 [SeSBP]	 and	 seated	 diastolic	 BP)	 and	
change	from	baseline	in	mean	SeBP	at	each	time	point	(observed	case	
approach)	 and	 end	 point	 (week	 8;	 last-	observation-	carried-	forward	
[LOCF]	approach);	and	the	proportion	of	patients	achieving	mean	SeBP	
<140/90	mm	Hg	and	SeSBP	<140	mm	Hg	at	end	point	(LOCF	approach).
Comprehensive	safety	assessments	reported	the	incidence	of	any	
treatment-	emergent	adverse	event	 (TEAE)	occurring	within	 the	 first	
8	weeks	of	the	double-	blind	period	or	until	permanent	discontinuation	
of	 study	 medication,	 whichever	 occurred	 first,	 including	 those	 that	
were	drug-	related	or	serious,	the	number	of	deaths,	and	the	incidence	
of	individual	TEAEs.
2.3 | Statistical analysis
The	primary	statistical	analysis	was	based	on	the	full	analysis	set,	de-
fined	as	all	patients	who	received	at	least	one	dose	of	study	medication	
and	had	a	nonmissing	baseline	and	at	least	one	nonmissing	postbase-
line	 SeBP	 value.	 Subanalyses	 were	 performed	 on	 subgroups	 that	
comprised	elderly	(aged	60–79	years)	and	nonelderly	(aged<60	years)	
patients	and	patients	with	CKD	(estimated	glomerular	 filtration	rate	
<60	mL/min/1.73	m2)	and	without	CKD	(estimated	glomerular	filtra-
tion	 rate	 ≥60	mL/min/1.73	m2).	 For	 subgroup	 analyses	 of	 elderly/
nonelderly	patients	 and	 those	with	 and	without	CKD,	 studies	were	
excluded	if	they	did	not	include	both	subgroups	for	direct	comparison	
within	studies.	Frequency	distributions	and	summary	statistics	for	the	
various	 parameters	 were	 calculated	 separately	 by	 treatment	 group	
and	time	point.	Mean	values	and	change	from	baseline	in	SeSBP	and	
seated	diastolic	BP	are	presented	using	the	observed	case	approach	at	
each	time	point	and	the	LOCF	approach	at	end	point	(week	8).	SeBP	
goal	data	are	reported	from	baseline	to	end	point	(LOCF).	Results	of	
the	 exploratory	 statistical	 analysis	 (two-	way	 analysis	 of	 covariance	
with	study	and	treatment	as	factors	and	baseline	SeSBP	as	a	covari-
ate)	of	absolute	change	on	mean	SeSBP	from	baseline	to	end	point	
(week	8;	LOCF)	are	presented	as	forest	plots.
3  | RESULTS
3.1 | Baseline characteristics
The	 integrated	 database	 consisted	 of	 53	 trials	 completed	 between	
1996	 and	 2012	 and	 represented	 34	320	 patients.	 Seven	 studies	
were	 included	 in	 the	meta-	analysis	according	 to	 the	 inclusion	crite-
ria	previously	stated	(Figure	S1	and	Table	S1).10,17-21	The	full	analysis	
set	 comprised	 5888	patients	 (OM	dual-	combination	 therapy	 group,	
n	=	3969;	OM	monotherapy	group,	n	=	1919).	Apparent	differences	
between	 the	 baseline	 characteristics	 of	 the	 OM	 dual-	combination	
therapy	and	OM	monotherapy	groups	were	small	(Table	1);	most	pa-
tients	were	men	and	white	with	a	mean	(SD)	age	of	54.8	(10.7)	years,	
mean	 (SD)	 body	mass	 index	of	 29.7	 (5.5)	 kg/m2,	 and	 a	mean	SeBP	
of	160.2/101.1	mm	Hg.	At	baseline,	 the	mean	estimated	glomerular	
filtration	rate	was	approximately	80.14	mL/min/1.73	m2,	and	12.6%	
of	all	patients	had	diabetes	mellitus.
The	 demographics	 of	 individual	 subgroups	 mostly	 mirrored	 the	
characteristics	of	the	full	analysis	set	with	the	exception	of	the	elderly	
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and	 patients	 with	 CKD	 whose	 mean	 baseline	 SeSBP	 values	 were	
slightly	higher	(Table	1).	The	rates	of	diabetes	mellitus	and	high	cardio-
vascular	risk	were	higher	among	elderly	patients	compared	with	non-
elderly	patients.	Similarly,	compared	with	patients	without	CKD,	the	
subgroup	of	patients	with	CKD	had	a	higher	incidence	of	diabetes	mel-
litus,	coronary	heart	disease,	heart	failure,	and	high	cardiovascular	risk.
3.2 | Efficacy
3.2.1 | Full analysis set
In	 the	 full	 analysis	 set,	 mean	 SeBP	 decreased	 rapidly	 towards	 the	
SeBP	goal	of	<140/90	mm	Hg	within	2	weeks	and	was	lower	at	end	
point	(week	8)	in	the	OM	dual-	combination	therapy	group	compared	
with	the	OM	monotherapy	group	(137.5/86.1	vs	144.4/89.9	mm	Hg,	
respectively)	(Figure	1A	and	Figure	S2A).	Corresponding	mean	SeBP	
changes	 from	 baseline	 at	 end	 point	 were	 −22.7/−15.0	mm	Hg	 and	
−16.0/−11.3	mm	Hg	 (Figure	2A	 and	 Figure	 S3A).	 The	 analysis	 of	
covariance	 of	 the	 absolute	 mean	 SeSBP	 change	 from	 baseline	 to	
end	 point	 showed	 an	 estimated	 overall	 treatment	 difference	 of	
6.67	mm	Hg	(95%	confidence	interval	[CI],	5.87–7.46)	in	favor	of	OM	
dual-	combination	therapy	(Figure	S4A).
3.2.2 | Elderly and nonelderly subgroups
The	 elderly	 and	 nonelderly	 subgroups	 comprised	 1901	 (OM	 dual-	
combination	therapy,	n	=	1314;	OM	monotherapy,	n	=	587)	and	3947	
(OM	dual-	combination	therapy,	n	=	2631;	OM	monotherapy,	n	=	1316)	
patients,	 respectively.	 Similar	 to	 the	 full	 analysis	 set,	mean	SeBP	was	
lower	 in	 the	OM	dual-	combination	 therapy	 vs	 the	OM	monotherapy	
groups	 at	 end	 point,	 irrespective	 of	 the	 age	 subgroup	 (elderly:	 dual-	 
combination	 therapy,	 141.1/85.4	mm	Hg;	 monotherapy,	 147.7/88.6 
mm	Hg;	 nonelderly:	 dual-	combination	 therapy,	 135.7/86.4	mm	Hg;	
monotherapy,	 142.7/90.5	mm	Hg)	 (Figure	1B,	 Figure	1C,	 Figure	 S2B,	
and	 Figure	 S2C).	Mean	 SeBP	 changes	 from	 baseline	 at	 end	 point	 in	
the	 two	 treatment	 arms	were	 also	 comparable	between	 the	 two	age	
subgroups	 (Figure	2B,	 Figure	2C,	 Figure	 S3B,	 and	 Figure	 S3C).	 The	
analysis	of	covariance	of	the	absolute	mean	SeSBP	change	from	base-
line	to	end	point	showed	an	estimated	overall	treatment	difference	of	
6.25	mm	Hg	(95%	CI,	4.76–7.74)	 in	the	elderly	subgroup	 (Figure	S4B)	
and	6.91	mm	Hg	(95%	CI,	5.97–7.86)	in	the	nonelderly	subgroup	(Figure	
S4C),	 both	 in	 favor	 of	OM	dual-	combination	 therapy.	 Supplementary	
analysis	using	a	revised	threshold	for	elderly	patients	(aged	≥70	years)	
was	performed	to	examine	the	effect	of	treatment	in	the	older	group.	
Baseline	SeBP,	mean	SeBP	change	from	baseline,	and	the	proportion	of	
patients	achieving	a	BP	goal	of	<140/90	mm	Hg	were	similar	between	
the	≥60-	and	≥70-	year	age	thresholds	(Table	S2).
3.2.3 | CKD and non- CKD subgroups
Of	all	patients	in	the	full	analysis	set,	642	had	CKD	(OM	dual-	combination	
therapy,	n	=	428;	OM	monotherapy,	n	=	214)	and	5245	patients	were	
assigned	 to	 the	 non-	CKD	 subgroup	 (OM	 dual-	combination	 therapy,	
n	=	3540;	OM	monotherapy,	n	=	1705).	At	study	end,	mean	SeBP	was	
lower	 among	patients	 receiving	OM	dual-	combination	 therapy	 com-
pared	with	OM	monotherapy	 (Figure	1D,	Figure	1E,	Figure	S2D,	and	
Figure	S2E).	Mean	SeSBP	at	end	point	was	higher	in	the	CKD	subgroup	
(OM	 dual-	combination	 therapy,	 141.8	mm	Hg;	 OM	 monotherapy,	
152.4	mm	Hg)	than	in	the	non-	CKD	subgroup	(OM	dual-	combination	
therapy,	137.0	mm	Hg;	OM	monotherapy,	143.4	mm	Hg).	Compared	
with	 OM	 monotherapy,	 mean	 SeBP	 changes	 from	 baseline	 were	
greater	among	patients	receiving	OM	dual-	combination	therapy	in	both	
the	CKD	and	non-	CKD	subgroups.	While	the	results	for	the	CKD	and	
non-	CKD	 subgroups	 receiving	OM	monotherapy	were	 similar	 (CKD,	
−14.9	mm	Hg;	non-	CKD,	−16.1	mm	Hg),	the	mean	SeBP	change	from	
baseline	 was	 larger	 among	 patients	 receiving	 OM	 dual-	combination	
therapy	 in	the	CKD	vs	the	non-	CKD	cohort	 (−24.3	vs	−22.5	mm	Hg,	
respectively)	(Figure	2D	and	Figure	2E).	The	analysis	of	covariance	of	
the	absolute	mean	SeSBP	change	from	baseline	to	end	point	showed	
an	 estimated	 overall	 treatment	 difference	 of	 9.50	mm	Hg	 (95%	 CI,	
3.09–15.92)	in	the	CKD	cohort	(Figure	S4D)	and	6.52	mm	Hg	(95%	CI,	
5.71–7.34)	in	the	non-	CKD	cohort	(Figure	S4E)	in	favor	of	OM	single-	
pill	dual-	combination	therapy.
3.3 | BP goal achievement
While	none	of	the	trials	were	randomized	to	two	different	BP	goals	
and	 evaluated	 cardiovascular	 outcomes,	 most	 studies	 in	 the	 inte-
grated	database	 targeted	an	SeBP	goal	of	<140/90	mm	Hg	during	
the	double-	blind	treatment	period	(Table	S1).	In	the	full	analysis	set,	
OM	dual-	combination	therapy	enabled	a	greater	proportion	of	pa-
tients	with	hypertension	to	achieve	an	SeBP	goal	of	<140/90	mm	Hg	
or	SeSBP	goal	of	<140	mm	Hg	at	end	point	compared	with	OM	mon-
otherapy	(51.2%	vs	34.7%,	respectively	[Figure	3A];	58.4%	vs	43.0%	
[Figure	3B]).	The	proportions	of	patients	achieving	SeBP	and	SeSBP	
goals	were	consistently	higher	with	OM	dual-	combination	therapy	
than	with	OM	monotherapy	across	all	patient	subgroups	(Figure	3).
More	 nonelderly	 vs	 elderly	 patients	 receiving	 OM	 dual-	
combination	 therapy	achieved	an	SeBP	goal	of	<140/90	mm	Hg	at	
end	point	(53.5%	vs	47.1%,	respectively)	(Figure	3A).	A	greater	pro-
portion	 of	 patients	 receiving	OM	 dual-	combination	 therapy	 in	 the	
non-	CKD	 subgroup	 achieved	 the	 SeBP	 goal	 of	 <140/90	mm	Hg	
vs	 those	 in	 the	 CKD	 subgroup	 (52.4%	 vs	 42.0%,	 respectively)	
(Figure	3A).	As	expected,	similar	trends	were	observed	when	exam-
ining	the	SeSBP	goal	of	<140	mm	Hg.	Greater	proportions	of	patients	
receiving	OM	dual-	combination	therapy	in	the	nonelderly	vs	elderly	
subgroups	(62.4%	vs	51.0%,	respectively)	and	non-	CKD	vs	CKD	sub-
groups	 (59.8%	vs	 46.7%,	 respectively)	 achieved	 the	 SeSBP	 goal	 at	
end	point	(Figure	3B).
3.4 | Safety
3.4.1 | Full analysis set
The	proportion	of	patients	experiencing	any	TEAE	was	comparable	
between	 the	OM	dual-	combination	 therapy	and	OM	monotherapy	
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F IGURE  1 Mean	seated	systolic	blood	pressure	(SeSBP)	from	baseline	to	end	point	(EP;	week	8,	observed	case	approach)	in	olmesartan	
medoxomil	(OM)	monotherapy	(Mono)	vs	dual-	combination	therapy	(Dual)	groups	in	patients	with	hypertension	for	the	(A)	full	analysis	set,	
(B)	elderly	subgroup,	(C)	nonelderly	subgroup,	(D)	chronic	kidney	disease	(CKD)	subgroup,	and	(E)	non-	CKD	subgroup.	LOCF	indicates	last	
observation	carried	forward
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groups	 (28.9%	 vs	 29.8%,	 respectively)	 (Table	2).	 The	 occurrence	
of	serious	TEAEs	was	also	similar	between	groups	 (0.7%	for	both),	
whereas	the	proportions	of	patients	with	drug-	related	TEAEs	were	
higher	 in	 the	 OM	 dual-	combination	 therapy	 group	 than	 in	 the	
monotherapy	group	(10.2%	vs	8.7%,	respectively).	No	deaths	were	
observed.	 The	 most	 frequently	 observed	 TEAEs	 were	 peripheral	
edema,	 headache,	 nasopharyngitis,	 dizziness,	 edema,	 fatigue,	 and	
back	 pain;	 however,	 the	 incidence	 of	 these	 individual	 events	 was	
F IGURE  2 Mean	seated	systolic	blood	pressure	(SeSBP)	change	from	baseline	to	end	point	(EP;	week	8,	observed	case	approach)	in	
olmesartan	medoxomil	(OM)	monotherapy	(Mono)	vs	dual-	combination	therapy	(Dual)	groups	in	patients	with	hypertension	for	the	(A)	full	
analysis	set,	(B)	elderly	subgroup,	(C)	nonelderly	subgroup,	(D)	chronic	kidney	disease	(CKD)	subgroup,	and	(E)	non-	CKD	subgroup.	LOCF	
indicates	last	observation	carried	forward
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low	and	similar	between	the	OM	dual-	combination	therapy	and	OM	
monotherapy	groups.
3.4.2 | Elderly and nonelderly subgroups
In	the	elderly	subgroup,	the	incidence	of	any	TEAE	was	lower	in	the	OM	
dual-	combination	 therapy	group	 than	 in	 the	OM	monotherapy	group	
(28.3%	vs	32.2%,	respectively)	(Table	2).	The	incidence	of	serious	TEAEs	
and	drug-	related	TEAEs	was	similar	between	treatment	groups.	More	
elderly	than	nonelderly	patients	experienced	a	TEAE	with	OM	mono-
therapy	(32.2%	vs	28.3%,	respectively).	The	incidence	of	any	TEAE	was	
similar	between	elderly	and	nonelderly	subgroups	for	patients	treated	
with	 OM	 dual-	combination	 therapy	 (28.3%	 vs	 29.1%,	 respectively)	
(Table	2).	Among	the	most	frequently	observed	TEAEs	in	the	full	analy-
sis	set,	there	were	no	noticeable	trends	or	differences	when	comparing	
treatment	groups	in	the	elderly	vs	nonelderly	subgroups,	with	the	excep-
tion	of	back	pain	with	OM	monotherapy	(2.2%	vs	0.8%,	respectively).
3.4.3 | CKD and non- CKD subgroups
In	the	CKD	subgroup,	the	incidence	of	any	TEAE	was	higher	in	the	OM	
monotherapy	group	than	in	the	OM	dual-	combination	therapy	group	
(39.7%	 vs	 32.9%,	 respectively)	 (Table	2).	 The	 incidence	 of	 serious	
TEAEs	was	similar	between	subgroups	receiving	monotherapy	or	dual-	
combination	therapy.	Compared	with	the	non-	CKD	subgroup,	the	inci-
dence	of	any	TEAE	and	any	drug-	related	TEAE	was	higher	in	the	CKD	
subgroup	(Table	2).	More	patients	experienced	peripheral	edema	and	
edema	in	the	CKD	subgroup	vs	the	non-	CKD	subgroup,	regardless	of	
the	treatment	received	(Table	2).
4  | DISCUSSION
Hypertension	 guidelines	 generally	 recommend	 starting	 patients	
with	 hypertension	 on	monotherapy,	with	 treatment	 options	 includ-
ing	 angiotensin-	converting	 enzyme	 inhibitors,	 ARBs,	 calcium	 chan-
nel	blockers,	 thiazide-	type	diuretics,	or	a	β-	blocker.	Guidelines	 such	
as	those	from	ASH/ISH	provide	advice	on	specific	drug	selection	by	
patient	 type.3	 If	 the	 initial	 treatment	 is	not	sufficient	 to	achieve	BP	
goals,	patients	may	be	prescribed	a	higher	dose	of	monotherapy	up	
to	a	maximum	dose	or	will	need	a	second	agent	from	a	different	drug	
class	 added	 to	 the	 initial	 drug	 choice.	Most	 patients	 are	 unable	 to	
achieve	BP	goals	with	monotherapy	alone,	and	combination	therapy	
with	two	or	more	agents	may	be	necessary	to	achieve	recommended	
BP	goals.5	The	current	meta-	analysis	examined	the	efficacy	and	safety	
of	 OM	 dual-	combination	 therapy	 vs	 OM	 monotherapy	 to	 provide	
further	 information	on	whether	 initiating	hypertension	management	
with	combination	therapy	may	be	the	preferred	treatment	approach	
for	patients	with	hypertension.
Despite	 slight	 variations	 in	 efficacy	 among	 the	 different	 pa-
tient	 populations	 examined	 in	 this	 meta-	analysis,	 both	 OM	 dual-	
combination	 therapy	and	OM	monotherapy	achieved	substantial	BP	
reductions	after	2	weeks	of	treatment,	which	were	maintained	through	
week	 8.	 Compared	 with	 OM	 monotherapy,	 OM	 dual-	combination	
therapy	demonstrated	greater	BP-	lowering	efficacy,	resulting	in	more	
patients	achieving	the	target	BP.	This	held	true	in	the	full	analysis	set	
and	all	 subgroup	populations	analyzed.	These	results	support	a	pre-
vious	meta-	analysis	 by	Wald	 and	 colleagues,22	which	 demonstrated	
the	superior	BP-	lowering	efficacy	of	combination	therapy.	Moreover,	
a	 retrospective	 analysis	 comparing	 combination	 antihypertensive	
therapy	regimens	vs	monotherapy	showed	that	patients	who	initially	
started	on	combination	therapy	were	more	likely	to	achieve	BP	goals	
after	12	months	of	therapy	compared	with	patients	who	had	started	
on	monotherapy.23	 In	 light	of	 these	findings,	 initiating	antihyperten-
sive	treatment	with	combination	therapy	may	be	preferred	over	initi-
ating	treatment	with	a	single	agent	alone.
The	 prevalence	 of	 hypertension	 increases	with	 age,	 being	 pres-
ent	 in	65%	of	patients	60	years	 and	older	 and	 in	76.5%	of	patients	
F IGURE  3 Proportion	of	patients	with	hypertension	in	each	
subgroup	analyzed	receiving	either	olmesartan	medoxomil	
(OM)	monotherapy	(Mono)	or	dual-	combination	therapy	(Dual)	
and	achieving	the	following	goals:	(A)	seated	blood	pressure	
<140/90	mm	Hg	and	(B)	seated	systolic	blood	pressure	<140	mm	Hg	
at	week	8	(last-	observation-	carried-	forward	approach).	CKD	indicates	
chronic	kidney	disease;	FAS,	full	analysis	set
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80	years	and	older.24	The	ESH/ESC	guidelines	recommend	the	use	of	
diuretics	and	calcium	channel	blockers	for	treating	isolated	systolic	hy-
pertension	in	the	elderly.4	In	this	meta-	analysis,	elderly	patients	aged	
60	to	79	years	who	received	OM	dual-	combination	therapy	achieved	
numerically	 similar	 SeSBP	 reductions	 compared	with	 nonelderly	 pa-
tients.	Additional	supplemental	analyses	demonstrated	similar	trends	
in	 the	 efficacy	 of	 OM	 dual-	combination	 therapy	 and	 monotherapy	
among	patients	70	years	and	older	vs	those	60	years	and	older.	Taken	
together,	 these	 results	 suggest	 that	OM	has	utility	 in	older	patients	
and	may	be	considered	as	a	suitable	initial	therapy	for	the	treatment	
of	hypertension.
Hypertension	and	CKD	are	closely	related	conditions.25 The preva-
lence	of	hypertension	is	even	greater	among	patients	with	CKD	than	in	
the	general	population.26	Consistent	with	the	results	observed	in	the	
full	 analysis	 set,	OM	dual-	combination	 therapy	was	 associated	with	
greater	 improvements	 than	 OM	monotherapy	 among	 patients	with	
and	without	CKD.	However,	the	magnitude	of	treatment	response	was	
smaller	in	the	CKD	vs	the	non-	CKD	subgroup,	and	a	smaller	propor-
tion	of	patients	with	CKD	achieved	BP	goals.11
A	 previous	meta-	analysis	 by	Wang	 and	 colleagues27	 showed	 no	
association	 between	 OM	 and	 an	 increased	 risk	 of	 adverse	 events	
compared	with	other	ARBs	(losartan,	candesartan,	valsartan,	and	irbe-
sartan).	 In	 the	 current	 analysis,	 both	OM	dual-	combination	 therapy	
and	OM	monotherapy	were	well	 tolerated	 in	 all	 patients	 examined,	
and	there	were	no	unexpected	safety	concerns.	A	higher	proportion	
of	TEAEs	and	drug-	related	TEAEs	was	reported	in	the	CKD	subgroup	
than	 in	 the	 full	analysis	 set	 for	both	 treatment	 regimens.	While	 this	
might	be	expected	among	a	cohort	of	patients	with	a	high	burden	of	
comorbidities,	it	is	unclear	whether	this	difference	is	clinically	relevant	
because	of	the	smaller	number	of	patients	in	the	CKD	subgroup.
Recent	clinical	trials	evaluating	outcomes	support	the	enhanced	
efficacy	of	combination	therapy	for	the	treatment	of	hypertension	
or	high	BP,	albeit	with	mixed	results	for	their	primary	end	points.	The	
SPRINT	 (Systolic	 Blood	 Pressure	 Intervention	Trial)	 study	 demon-
strated	 a	 significant	 reduction	 in	 the	 risk	 of	 major	 cardiovascular	
events	when	previously	treated	patients	with	high-	risk	hypertension	
were	treated	to	an	intensive	BP	goal	of	<120	mm	Hg	vs	<140	mm	Hg;	
however,	this	was	achieved	by	approximately	one	more	medication	
over	 those	patients	 treated	 to	 the	more	 conservative	 goal	 (2.8	vs	
1.8	 medications,	 respectively).28	 The	 HOPE-	3	 (Heart	 Outcomes	
Prevention	 Evaluation-	3)	 study	 in	 patients	with	 intermediate	 car-
diovascular	risk	 (≈40%	with	baseline	hypertension)	revealed	that	a	
combination	of	the	ARB	candesartan	and	hydrochlorothiazide	low-
ered	BP	(−10.0/−5.7	mm	Hg)	but	did	not	decrease	the	risk	of	major	
cardiovascular	events	over	placebo.29	In	subgroup	analysis,	patients	
in	the	upper	third	of	baseline	systolic	BP	(>143.5	mm	Hg)	showed	a	
significantly	decreased	risk	in	major	cardiovascular	events.29
5  | STUDY STRENGTHS AND LIMITATIONS
A	major	 strength	of	 this	meta-	analysis	was	 the	 large	 sample	 size	of	
patients	in	the	full	analysis	set	and	elderly/nonelderly	subgroups	taken	
from	pooled	randomized	controlled	trials.	While	the	definition	of	el-
derly	used	in	this	analysis	(aged	≥60	years)	differs	from	some	organi-
zational	 guidelines,	 supplemental	 analyses	 examining	 an	 alternative	
definition	of	elderly	(aged	≥70	years)	suggested	little	difference	in	the	
efficacy	of	OM	dual-	combination	or	monotherapy.	A	limitation	to	this	
meta-	analysis	was	the	short	duration	of	the	study,	which	was	not	ex-
tensive	enough	to	identify	rare	serious	adverse	events.
6  | CONCLUSIONS
In	 this	 patient-	level	meta-	analysis	 of	 randomized,	 double-	blind,	 pla-
cebo-	or	active-	controlled,	phase	2	to	4	clinical	trials	in	patients	with	
hypertension,	OM	single-	pill	dual-	combination	therapy	was	well	toler-
ated	and	more	effective	in	lowering	BP	than	OM	monotherapy,	ena-
bling	more	patients	to	achieve	guideline-	recommended	BP	goals	with	
a	preferable	safety	profile.
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